Anti-SSA (Ro) Antibodies (Anti-Ro / SSA)
Autoantibodies directed against the Ro52 and Ro60 ribonucleoprotein complexes involved in RNA quality control.
Standard vs. Optimal Reference RangesEU/mL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<20.0 EU/mL (negative)
General reference distribution across unselected commercial populations.
<10.0 EU/mL
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Forms immune complexes that deposit in salivary glands, lacrimal glands, and maternal-fetal cardiac conduction systems.
Differential Diagnosis
Elevated Levels (Anti-Ro / SSA High)
- •Sjogren syndrome (positive in 70% to 90%)
- •Systemic Lupus Erythematosus (positive in 30% to 50%)
- •Neonatal lupus / Congenital heart block
Low Levels (Anti-Ro / SSA Low)
- •Normal immune tolerance
- •Absence of connective tissue disease
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for Anti-Ro / SSA
- Targeted organ system imaging or functional dynamic testing related to autoimmune ribonucleoprotein target
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Anti-SSA (Ro) Antibodies - The New England Journal of Medicine (2021). PMID: 33990124
- [2]Anti-Ro / SSA Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35222901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Anti-SSA (Ro) Antibodies (Anti-Ro / SSA) into overall healthspan optimization.